NCT05064345View on ClinicalTrials.gov

A Study to Evaluate HB0034 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions
Healthy
Interventions
DRUG

HB0034

Recombinant Humanized Anti-IL-36R Monoclonal antibody

DRUG

Placebo

Palcebo

Trial Locations (1)

Unknown

New zealand Clinical Research, Auckland

All Listed Sponsors
lead

Shanghai Huaota Biopharmaceutical Co., Ltd.

INDUSTRY

NCT05064345 - A Study to Evaluate HB0034 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter